Physician profile

Sandhya Pattem

Family Medicine · Jupiter, FL

NPI 1639198856

$399.90

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$160.47

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Lilly USA, LLC $138.36 2022-2023 Mounjaro
Novartis Pharmaceuticals Corporation $100.00 2019
Novo Nordisk INC $64.02 2022-2024 Ozempic, Rybelsus, Wegovy
Sunovion Pharmaceuticals INC. $29.71 2019
Astrazeneca Pharmaceuticals Lp $27.97 2019-2022
Abbvie INC. $23.53 2022
Glaxosmithkline, LLC. $16.31 2023 Shingrix, Trelegy Ellipta

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sandhya Pattem

$399.90

in general payments reported 2019-2025

Years
2019-2024
Top company
Lilly USA, LLC

https://glasscript.com/doctor/28309/sandhya-pattem

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.